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Background: Most previous studies of chromosomal mosaicism in IVF embryos were performed by fluorescence
in situ hybridization (FISH) methods. While there are reports implicating chromosome aneuploidy in implantation
failure following transfer and pregnancy loss by spontaneous miscarriage, the significance of mosaicism for the
developmental potential of growing embryos is unknown. However, the low prevalence of chromosomal
mosaicism in chorionic villus sampling and amniotic fluid specimens suggests the presence of selection against
mosaic embryos for implantation and early pregnancy. The absence of evidence for selective allocation of abnormal
cells to the trophectoderm (TE) of mosaic blastocysts permits these cells to be a good proxy for embryonic
mosaicism detection by chromosomal microarrays (CMA). The purpose of this study was to establish the limits of
detection and the prevalence of chromosome mosaicism in day 5/6 human embryos using CMA with TE biopsies.
Results: From reconstitution experiments we established log2 ratio thresholds for mosaicism detection. These
studies indicated that chromosomal mosaicism at levels as low as between 25-37% can be consistently identified.
Follow-up studies by FISH on non-transferred abnormal embryos confirmed the diagnostic accuracy of CMA testing.
The number of cells in a TE biopsy can influence mosaicism detection.
Conclusions: Chromosomal microarrays can detect mosaicism in TE biopsies when present at levels as low as
between 25-37% and the prevalence of day 5/6 blastocysts which were mosaic and had no other abnormalities
reached 15% among a cohort of 551 embryos examined. Validated protocols for establishing detection thresholds
for mosaicism are important to reduce the likelihood of transferring abnormal embryos.Background
Chromosomal mosaicism has been associated with hu-
man morbidity but the phenotypic manifestations are de-
pendent on mosaicism level, the chromosome involved,
and tissue distribution. An accurate assessment of the
prevalence of mosaicism in the newborn population is un-
certain because of ascertainment bias toward abnormal
clinical presentations. However, in prenatal specimens
large studies indicate that mosaicism is found in 0.20-
0.25% of amniotic fluid [1,2] and 0.8-2% of chorionic villus
samples [3-6]. Chromosomal mosaicism is significantly
higher in IVF created embryos than in other prenatal
specimens. In a recent literature review and meta-analysis* Correspondence: vnovik@givf.com
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cism, van Echten-Arends et al. [7] reported that mosai-
cism is the most common chromosome constitution in
spare IVF embryos and was found in 73% of all embryos.
Of these embryos, 67% were at cleavage stage and most of
the studies used FISH to determine chromosome consti-
tution as well as spare embryos that were deemed unsuit-
able for transfer. Using chromosomal microarrays with
cleavage stage embryos, Mertzamidou et al. [8] also found
71% of embryos to be mosaic. Most previous studies as-
sessed mosaicism at cleavage stage from spare or arrested
embryos. There is currently little data on chromosomal
mosaicism derived from progressing day 5/6 hatching
blastocysts.
Chromosomal microarrays have replaced FISH and com-
parative genomic hybridization (CGH) based methods fortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Novik et al. Molecular Cytogenetics 2014, 7:18 Page 2 of 9
http://www.molecularcytogenetics.org/content/7/1/18assessing aneuploidy in developing embryos [9,10] and an-
euploidy has been implicated in implantation failure and
pregnancy loss by spontaneous miscarriage following IVF
embryo transfer [11,12]. The relatively low levels of mo-
saicism reported in prenatal specimens and the decrea-
sing frequency of mosaicism with increased gestational
age suggests the presence of selective pressure against em-
bryos with high levels of mosaicism for ongoing preg-
nancy. Although mosaicism has been reported in embryos
using CMAs with TE biopsies [13,14], the effects of this
mosaicism on embryonic development, implantation, and
pregnancy outcome is currently unknown and the degree
to which a CMA result from a small sample of embryonic
cells at day 5/6 accurately reflects embryonic mosaicism
levels has not been adequately described. We report here
on the limits of mosaicism detection using cell mixing
experiments, the accuracy of mosaicism detection from
FISH follow-up studies, and estimate the prevalence of
mosaicism at the blastocyst stage of development.
Results
Reconstitution experiments and establishment of log2
ratios to detect chromosomal mosaicism
To mimic chromosomal gains and losses, mixing ex-
periments with different ratios of amplified DNA from
aneuploid and euploid cell lines as well as clinical sam-
ples were used as described in the Methods section. The
sample size of five cells was chosen for SurePlex ampli-
fication because it is similar to the size of an average
trophectoderm biopsy. Individual log2 ratios and average
log2 ratios were determined for trisomy 13 and trisomy
21 samples at different levels of mosaicism (Additional
file 1) and likewise for monosomy 6 and monosomy 22
(Additional file 2). A clear and definitive visualization of
all hybridization signals above or below the 0 log2 ratio
line, the first indicative sign of chromosomal mosaicism,
was detected at levels as low as between 25-37.5% (a
log2 ratio of +0.135) for gains and at 37-50% (an average
log2 ratio of -0.153) for losses. The Additional files 3 and
4 provide illustrations of chromosomal aneuploidy at 0,
25, 37.5, 50, 75 and 100% for a trisomy (+13) and a
monosomy (-6), respectively. Also of note is that the
visual detection of chromosomal mosaicism is largely
dependent on the quality of the starting material. Troph-
ectoderm biopsy samples from degenerating embryos
usually lead to a noisy pattern of array hybridization
profiles which could obscure the detection of mosaicism.
We blind-tested twelve mosaic and non-mosaic samples
to further confirm our criteria – all samples were identi-
fied correctly (Additional file 5).
FISH follow-up analysis of research embryos
The diagnostic accuracy of our CMA testing was as-
sessed by FISH follow-up with non-transferred abnormalembryos. Only chromosomes identified to be aneuploid
(non-mosaic or mosaic) by CMA were targeted by FISH
probes. The results for embryos diagnosed as having at
least one non-mosaic chromosome aneuploidy are shown
in Table 1. For scoring purposes, an embryo FISH result
was considered abnormal and concordant with the TE
result when nuclei had the same abnormality identi-
fied by CMA or a complementary abnormality (e.g. +21
or -21) as could be found in mosaic embryos. Of the 26
embryos identified to be non-mosaic by CMA, FISH
follow-up confirmed abnormalities in all of them (100%)
but 50% of the embryos in this group were mosaic
for at least one chromosome by FISH. The results for
embryos diagnosed by CMA as having at least one mo-
saic chromosome aneuploidy are shown in Table 2. Of
the 21 embryos in this group, 20 embryos were ab-
normal (95%). Nineteen embryos (90%) were confirmed
as having at least one mosaic chromosome and one
embryo was found by FISH to be non-mosaic aneu-
ploid. For embryos with two or more mosaic chro-
mosomes, FISH demonstrated that all these embryos
contained some non-mosaic cells and thus did not repre-
sent aneuploid-aneuploid mosaic embryos. These results
confirm the diagnostic accuracy of CMA testing for both
non-mosaic and mosaic embryo aneuploidy categories
and thus permit a realistic estimation of the prevalence of
euploidy and aneuploidy in a larger cohort of day 5/6
blastocysts.Aneuploidy and mosaicism in day 5/6 embryos
From CMA analysis of 551 blastocysts obtained during
IVF cycles at our clinic (Table 3), 52.5% were euploid
and 47.5% were aneuploid. In the chromosomally aneu-
ploid group, 40.5% were non-mosaic, 31.6% displayed
chromosome mosaicism only (using the established cri-
teria for chromosomal mosaicism described above), and
the remaining abnormal embryos (27.9%) displayed both
mosaic and non-mosaic forms of aneuploidy. Given that
our follow-up studies indicated that about one half of
CMA diagnosed non-mosaic embryos were mosaic, then
the true number of embryos that are non-mosaic aneu-
ploid is likely smaller and the mosaic only and mixed
non-mosaic/mosaic aneuploid subgroups are likely lar-
ger. When this embryo cohort was analyzed by maternal
age (Table 4), the percent of euploid embryos decreased
with increased maternal age. There was also a direct
relationship between increased maternal age and per-
cent of non-mosaic aneuploid embryos; the ratio of
non-mosaic aneuploid embryos to euploid embryos in
the 25-34 age group was 0.24 but 1.67 in the age 40-42
group. The ratio of mosaic only embryos to euploid em-
bryos was 0.26 in the youngest age group and 0.33 in the
oldest group.
Table 1 Follow-up FISH data for embryos diagnosed with non-mosaic aneuploidy by CMA
Specimen
designation
TE cell # CMA
aneuploidya
Log2 ratio Abnormal nuclei
by FISH (%)b
Non-mosaicc Mosaicd Embryo confirmed
abnormale
1 NM 6 −X −0.501 100 Yes No Yes
−13 −0.461 100 Yes No
2 NM 3 +15 0.284 84 No Yes Yes
3 NM 2 −X −0.721 37 No Yes Yes
+Y 0.440 47 No Yes
+21 0.369 47 No Yes
4 NM 2 −13 −0.409 21 No Yes Yes
−18 −0.446 47 No Yes
5 NM 6 −22 −0.430 100 Yes No Yes
6 NM 5 −6 −0.487 100 Yes No Yes
7 NM 7 −14 −0.374 94 Yes No Yes
8 NM 7 +15 0.300 94 Yes No Yes
9 NM 2 −Y −0.237 0 No No Yes
+21 0.465 92 Yes No
10 NM 5 +15 0.317 97 Yes No Yes
11 NM 2 −15 −0.508 74 No Yes Yes
12 NM 4 −19 −0.382 91 Yes No Yes
13 NM 3 +5 0.294 80 No Yes Yes
+14 0.249 83 No Yes
−18 −0.529 100 Yes No
14 NM 3 −14 −0.555 73 No Yes Yes
15 NM 1 −22 −0.395 94 Yes No Yes
16 NM 4 −8 −0.642 97 Yes No Yes
+11 0.336 97 Yes No
17 NM 3 −21 −0.432 73 No Yes Yes
18 NM 2 +9 0.375 94 Yes No Yes
19 NM 5 +16 0.253 86 No Yes Yes
20 NM 4 −22 −0.407 87 No Yes Yes
21 NM 3 −4 −0.440 12 No Yes Yes
−10 −1.540 0 No No
22 NM 1−2 −X −0.485 87 No Yes Yes
+13 0.398 71 No Yes
23 NM 4 +8 0.288 94 Yes No Yes
+22 0.268 97 Yes No
24 NM 8 −19 −0.417 80 No Yes Yes
25 NM 3 +22 +0.256 86 No Yes Yes
26 NM 3 −10 −0.561 94 Yes No Yes
aAll chromosomes listed as abnormal in the embryos of this table were identified by BlueFuse software to be aneuploid.
bA nucleus is considered abnormal by FISH if there is a loss or gain of the chromosome identified by CMA to be aneuploid.
cA non-mosaic CMA result is considered concordant with FISH if ≥ 90% of follow-up embryo cells have a FISH signal pattern consistent with the CMA data.
dA mosaic CMA result is considered concordant with FISH if ≥ 10% and < 90% of follow-up embryo cells have a FISH signal pattern consistent with the CMA data.
eAn embryo follow-up result is considered abnormal and concordant with an abnormal CMA result if at least one chromosome in an embryo identified by CMA as
abnormal is confirmed by FISH.
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Chromosomal microarrays have documented aneuploidy
and mosaicism to be common at the blastocyst stage
of development [7,13-16]. While arrays can confidently
identify non-mosaic aneuploidy, there is less certaintyregarding the technical limits of detection of mosaicism
especially when the biopsy cell number is limited and
whole genome amplification is required. Because micro-
array data is dependent on array platform, the quality
of DNA and software algorithms, it is important that
Table 2 Follow-up FISH data for embryos diagnosed with mosaic aneuploidy by CMA
Specimen
designation
TE cell # CMA
aneuploidya
Log2 ratio Abnormal nuclei
by FISH %b
Non-mosaicc Mosaicd Embryo confirmed
abnormale
1 M 2 +14 0.193 97 Yes No Yes
2 M 4 +8 0.206 53 No Yes Yes
3 M 3 −1 −0.155 10 No Yes Yes
4 M 5 −4 −0.235 21 No Yes Yes
5 M 4 −19 −0.173 20 No Yes Yes
6 M 4 −4 −0.154 10 No Yes Yes
7 M 4 +5 0.220 27 No Yes Yes
+10 0.133 6 No No
8 M 4 −8 −0.203 20 No Yes Yes
9 M 3 −14 −0.178 12 No Yes Yes
10 M 2 −9 −0.183 7 No No No
11 M 4 +15 0.230 63 No Yes Yes
+17 0.164 20 No Yes
12 M 11 −8 −0.280 19 No Yes Yes
−11 −0.141 28 No Yes
13 M 7 −8 −0.230 71 No Yes Yes
14 M 4 +2 0.211 40 No Yes Yes
+8 0.181 26 No Yes
15 M 4 +22 0.136 16 No Yes Yes
16 M 4 +1 0.168 15 No Yes Yes
17 M 4 −18 −0.216 58 No Yes Yes
18 M 4 −8 −0.199 43 No Yes Yes
+16 0.179 30 No Yes
19 M 2 −3 −0.146 23 No Yes Yes
+X 0.159 19 No Yes
20 M 4 +19 0.159 23 No Yes Yes
+X 0.149 26 No Yes
21 M 3−4 −19 −0.162 56 No Yes Yes
aEmbryos listed in this table were identified by CMA to have at least one mosaic chromosome aneuploidy.
bA nucleus is considered abnormal by FISH if there is a loss or gain of the chromosome identified by CMA to be aneuploid.
cA non-mosaic CMA result is considered concordant with FISH if ≥ 90% of follow-up embryo cells have a FISH signal pattern consistent with the CMA data.
dA mosaic CMA result is considered concordant with FISH if ≥ 10% and < 90% of follow-up embryo cells have a FISH signal pattern consistent with the CMA data.
eAn embryo follow-up result is considered abnormal and concordant with an abnormal CMA result if at least one chromosome in an embryo identified by CMA as
abnormal is confirmed by FISH.
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assessing mosaicism. This has been recommended by
both the American College of Medical Genetics and the
European best practices guidelines for constitutional mi-
croarray testing [17,18]. As a prerequisite for assessing





551 289/551 (52.5) 106/262 (40.5
aAll age groups combined: the maternal age averaged across all blastocysts in coho
eggs were used in 21 cycles; the maternal age for this group was calculated as 33.
bEmbryo was called aneuploid if at least one chromosome was identified by BlueFu
cEmbryo was called mosaic if at least one chromosome had a log2 ratio CMA result
hybridization signals.mosaicism, we first determined the limits of detection of
mosaicism by performing reconstitution experiments
using DNA mixed from normal and aneuploid sam-
ples and analyzing CMA results for mosaicism detection
using BlueGnome’s 24sure array and data generated by
BlueGnome’s BlueFuse Multi software.Abnormal, n = 262 (47.5%)
) Aneuploidb and mosaicc (%) Mosaicc (%)
) 73/262 (27.9) 83/262 (31.6)
rt was 33.9. Embryos obtained from 120 PGD cycles (103 patients total). Donor
se software to be aneuploid at diagnosis.
of ≥ +0.130 or ≤ -0.150 at diagnosis and a homogeneous deflection of all





Normal (%) Abnormal: n varies according to the age group (%)
Aneuploida (%) Aneuploida and mosaicb (%) Mosaicb (%)
25–34 338 202/338 (59.8) 48/136 (35.3) 35/136 (25.8) 53/136 (38.9)
35–39 163 75/163 (46) 38/88 (43.2) 24/88 (27.3) 26/88 (29.5)
40–42 50 12/50 (24) 20/38 (52.6) 14/38 (36.9) 4/38 (10.5)
aEmbryo was called aneuploid when BlueFuse software called a chromosome(s) gain or loss.
bEmbryo was called mosaic if at least one chromosome had a log2 ratio CMA result of ≥ +0.130 or ≤ -0.150 at diagnosis and a homogeneous deflection of all
hybridization signals.
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racterize the approximate lowest levels of mosaicism
that could be confirmed from follow-up studies as biolo-
gically real. We interpreted the presence of whole chro-
mosome mosaicism when a clear visual deflection of all
hybridization signals above or below the log2 0 ratio value
was discernible for any chromosome. For chromosome
gains, mosaicism as low as between 25-37% can be ob-
served which corresponds to a log2 ratio of approxi-
mately +0.13 and for chromosome losses, mosaicism
as low as between 37-50% can be observed which cor-
responds to a log2 ratio of approximately -0.15 (see
Additional files 1, 2, 3 and 4). There was some variability
around these cut-off levels, as expected, because BAC ar-
rays have less reproducibility and more batch-to-batch
variation when compared to oligonucleotide constructed
arrays [19]. Variation in array lots and in whole genome
DNA amplification with small samples can also influence
log2 ratios. In addition, there are also likely to be minor
chromosome specific log2 ratio differences between differ-
ent individual chromosome trisomies and monosomies
due to variation in the number of probes for each chro-
mosome and their unique hybridization properties. The
predicted log2 ratio for a chromosome gain is +0.58 [log2
(3/2)] and that for a chromosome loss is -1.0 [log2 (1/2)].
It might be expected, then, that deflection of hybridization
signals below the log2 ratio 0 value would be more prom-
inent for chromosome losses compared to gains and that
mosaicism for losses would be relatively easier to identify
than for gains. Others have demonstrated that copy num-
ber variation (CNV) duplications are obscured by lower
levels of maternal cell contamination than for similarly
sized CNV deletions [20]. In patient samples displaying
both a chromosome gain(s) and loss(es), we usually find
the deviation from the log2 0 line is greater for chromo-
some losses than for chromosome gains (unpublished
observations). In these situations, losses and gains were
determined from the same pool of amplified DNA. How-
ever, in our reconstruction experiments where we did not
detect lower levels of mosaicism for chromosome losses
compared to chromosome gains, these results are likely to
be an experimental artifact due to the combining of diffe-
rent pools of amplified DNA products where there could
have been minor differences in the quality of the DNAprior to whole genome amplification. The results we ob-
tained for chromosome gains are consistent with those of
Mamas et al. [21] who used the same array platform and
software but analyzed DNA extracted from mixed popula-
tions of aneuploid and normal cells to simulate mosaicism
in PGD specimens. They noted a shift in the log2 ratio
when mosaicism reached 25% and confidently interpreted
the presence of mosaicism when it was present at the 50%
level for chromosome gains. They did not present data for
chromosome losses. Northrop et al. [14] combined cells,
in graded proportions, from normal male and female cell
lines to simulate mosaic blastocyst biopsies and then ana-
lyzed these mixed cell populations using a 262 K SNP
microarray. Their results indicated that identification
of monosomy X mosaicism (male cells) was detectable
when > 25% of cells in the population were male. Scott
et al. [22] mixed DNA samples extracted from cytogeneti-
cally normal and abnormal sources, without whole gen-
ome amplification, to determine the limits of mosaicism
detection using a 44 K oligonucleotide array. Mosaicism
as low as 10% for both gains and losses of whole chromo-
somes was detectable when data from dye-reversed rep-
licates were combined but this detection limit rose to
20-30% mosaicism in the absence of dye-reversed rep-
licates. While high resolution arrays may detect lower
levels of mosaicism, the primary purpose of array testing
in the PGD setting is to identify whole chromosome aneu-
ploidy without the additional uncertainty associated with
the interpretation of the clinical significance of small copy
number variants. Therefore, with this clinical objective in
mind and with the technical limitations imposed by small
sample sizes and the requirement for whole genome amp-
lification, embryo mosaicism of less than approximately
25% will not likely be detectable.
After establishing threshold levels for mosaicism iden-
tification, these criteria were applied to classify embryos
as euploid, non-mosaic aneuploid, or mosaic aneuploid.
Follow-up FISH studies of our abnormal embryos were
evaluated to assess the diagnostic accuracy of CMA tes-
ting. In a series of 47 embryos with follow-up data, 26 em-
bryos were considered to be non-mosaic by CMA. While
FISH confirmed whole chromosome aneuploidy in all of
the embryos (100%), 13 embryos in this group (50%) were
mosaic by FISH for at least one chromosome. Among the
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tion of mosaic cells between the inner cell mass (ICM)
and TE or the effect of sample size. Recent studies of cells
derived from TE and ICM and analyzed by CMAs by
Johnson et al. [23] and Northrup et al. [14] do not support
the preferential segregation of aneuploid cells to the TE.
These studies are also consistent with an earlier report by
Evsikov and Verlinsky using FISH [24]. Because more em-
bryonic cells are available for reanalysis by FISH compared
to the limited number of cells in a TE biopsy, it is likely
that some embryos diagnosed as non-mosaic aneuploid
by CMA will display mosaicism by FISH due to sampling
error. This observation has been reported by Fragouli
et al. [13] when they compared CGH data and FISH
reanalysis results. Therefore, we reported an embryo as
confirmed abnormal if at least one chromosome in an em-
bryo identified by CMA was also identified as abnormal
(non-mosaic or mosaic) by FISH. These criteria are similar
to that utilized by Gutierrez-Mateo et al. [25] in their
study of embryo reanalysis by FISH. Another considera-
tion regarding mosaic embryos is that embryos can be
aneuploid-aneuploid or aneuploid-euploid. While the clin-
ical significance of low levels of mosaicism is uncertain,
most likely aneuploid-aneuploid mosaic embryos (no eu-
ploid cells) will not lead to viable live births. In our study
all mosaic embryos were aneuploid-euploid.
If there is an equal distribution of cells within the em-
bryo, a large biopsy will inherently better reflect the total
embryonic population and will be less susceptible to
sample bias compared to a small biopsy. Of the 13 em-
bryos in the CMA non-mosaic category which by FISH
follow-up were identified as mosaic, 10/13 (78%) of these
embryos had three or less cells in the biopsy. Among 21
embryos identified as mosaic by CMA, 20 (95%) were
confirmed as abnormal by FISH. Interestingly, one em-
bryo in this group was non-mosaic by FISH. The single
case with a discordant result had 7% of nuclei with an
aneuploid FISH signal which was slightly below our
threshold for scoring this embryo as abnormal. In this
study we only attempted to confirm mosaicism by FISH
for chromosomes identified by CMA to be abnormal.
While it is possible that this approach underestimated
the number of mosaic chromosomes present in embryos,
this is not likely because in our preclinical validation
studies we established high analytical sensitivity using
CMA. No FISH follow-up studies were performed on
embryos identified by CMA to be euploid because these
embryos were generally not available for further study
and because our preclinical validation experiments dem-
onstrated high analytical specificity.
CMA testing of TE biopsies from unselected blasto-
cyst populations demonstrates high levels of chromosom-
ally abnormal embryos. In a recent randomized clinical
trial, Yang et al. [16] reported aneuploidy in 56.6% ofblastocysts from young, good prognosis patients. With
aCGH(CMA) or CGH, Fragouli et al. [13] reported 42.3%
blastocyst euploidy, 30% non-mosaic aneuploidy, and
32.4% mosaic aneuploidy. Using the mosaicism thresholds
described above, we analyzed 551 day 5/6 embryos by
CMA. Of these, 52.5% were diagnosed to be euploid and
47.5% to be chromosomally abnormal. In the abnormal
embryo population, 40.5% were non-mosaic aneuploid,
31.6% mosaic only, and 27.9% of embryos displayed non-
mosaic and mosaic aneuploidy together. However, based
on our FISH follow-up studies that showed that about one
half of CMA diagnosed non-mosaic embryos were, in fact,
mosaic because of skewed sampling, then the size of the
mosaic class of embryos would be expected to be larger.
When the same CMA data were analyzed by age group,
younger women (25-34 years old), as expected, had the
highest percent of euploid embryos (59.8%) and older
women (40-42 years old) had the lowest percent of eu-
ploid embryos (24%). The ratio of non-mosaic aneuploid
embryos to euploid embryos was 0.24 in the youngest age
group and 1.67 in the oldest age group. This observation
is consistent with a maternal age effect for meiotic non-
disjunction. The ratio of mosaic only embryos to euploid
embryos was relatively constant among the different age
groups: 0.26, 0.35, and 0.33 for the 25-34, 35-39, and 40-
42 year old patients, respectively. While the number of
embryos available for study for the 40-42 year old group
was small and thus insufficient for statistical comparison,
there does not appear to be striking differences between
these groups for the mosaic only category. If larger studies
confirm this observation, then mitotic non-disjunction
leading to mosaicism would appear to be a random event
unrelated to maternal age. With demonstrated maternal
age effects on meiotic non-disjunction as well as egg co-
hort size, the practical significance of a steady rate of mi-
totic non-disjunction across age groups is that it can lead
to a less complicated estimation of the number of normal
blastocysts that can be expected given the number of fer-
tilized eggs available and a women’s maternal age.
This study confirms that mosaicism is common in day
5/6 blastocysts and that CMA testing can identify a sig-
nificant proportion of these embryos. FISH follow-up
studies confirm that mosaicism suggested by CMA pro-
files is not likely to be due to technical artifacts of the
arrays and thus the likelihood that normal embryos are
misidentified and not transferred is reduced. Some ab-
normal mosaic embryos, however, may not be identified
because the TE biopsy may not be representative of the
embryo and it may yield only euploid cells. It is import-
ant, then, that laboratories perform pre-clinical mixing
experiments to validate the performance characteristics
of their array platform and to establish detection thres-
holds for mosaicism in order to reduce the chances of
transferring abnormal embryos. Preliminary studies in
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that this approach can also be sensitive in the identifica-
tion of blastocyst mosaicism.
Conclusions
In this study we report the data from reconstitution expe-
riments using DNA mixed from normal and aneuploidy
specimens to define the limits of detection of mosaicism
using CMA as well as the accuracy of aneuploidy and mo-
saic aneuploidy identification in blastocyst TE samples.
Our findings underscore the challenges in the identifica-
tion of embryos with low levels of chromosomal mosai-
cism and the importance of obtaining sufficient cells in
the TE specimen to minimize the effects of skewed biopsy
sampling.
Methods
Study design and materials
Experimental and laboratory studies were performed on
karyotypically defined human fibroblast cell lines and
human IVF embryos donated to quality assurance follow
up. Patients’ CMA data was calculated based on analysis
of 551 embryos obtained from 120 IVF cycles (103 pa-
tients total).
Ovarian stimulation/IVF/TE biopsy
All embryos analyzed in this study were obtained dur-
ing IVF cycles following ovarian stimulation by standard
protocols as administered by the patients’ physicians. In-
tracytoplasmic sperm injection (ICSI) and day 3 assisted
hatching procedures were routinely performed on all
cases as required by our PGD protocol. The trophecto-
derm biopsy was done on day 5/6 hatching blastocysts,
with an average biopsy size of around four-five cells
based on microscopic estimation using a laser on the con-
stricted area of herniating TE. A modification of Gardner’s
blastocyst scoring system [26] was used for grading em-
bryos that became hatching blastocysts on day 5 or day 6.
In short, embryos were rated based on three criteria: (i)
the degree of expansion – 6.2 to 6.6, (ii) the quality of
inner cell mass – A to C, (iii) the quality of trophectoderm
cells – X to Z. About 29% of all hatching blastocysts were
scored as AX, ~25% were scored as AY, ~ 11% were score
as BX, ~30% were scored as BY and ~5% were scored as
AZ, CX, BZ.
Reconstitution experiments
DNAs from aneuploid and euploid cell lines as well
as clinical samples were mixed in different ratios (1:7
[12.5%], 1:3 [25%], 3:5 [37.5%], 1:1 [50%], 5:3 [62.5%],
3:1 [75%] and 7:1 [87.5%]) for reconstitution experi-
ments. For chromosomal gains, trisomy 13, trisomy 21
and euploid male cell lines (GM00526, GM02067B and
GM05386B, respectively; (Coriell Cell Repositories, USA)were used. DNA from five cells of each cell line was amp-
lified using the SurePlex kit (BlueGnome, UK), mixed, and
assayed by array comparative genomic hybridization
(aCGH; BlueGnome). Reconstitution experiments to ob-
tain the individual log2 ratios for trisomy 13 and trisomy
21 were independently repeated at least three times. For
chromosomal losses, amplified DNA from patient speci-
mens that were identified by CMA and confirmed by
FISH to have full monosomy 6 and monosomy 22 were
used. The trophectoderm biopsy samples from these sour-
ces contained five cells. For all reconstitution experiments,
log2 ratios were calculated to express deviation of CMA
profiles at each level of sample mixing. We interpreted the
presence of mosaicism when all hybridization signals for a
chromosome were uniform and visually separated above
or below the 0 log2 ratio line; that is, when there was
no scatter of individual hybridization signals or small
groups of hybridization signals that closely approached or
touched the 0 log2 ratio line (see Additional files 3 and 4).
For a diagram of a reconstitution experiment please see
the Additional file 6.
CMA (aCGH)
The BlueGnome SurePlex and 24sure array kits were
used for whole genome amplification (WGA) and sub-
sequent labeling/hybridization of DNAs derived from
fibroblast cells and TE specimens, following the manu-
facturer’s protocol (BlueGnome, UK). Slides were scan-
ned using PowerScanner (Tecan, Switzerland) and TIFF
images were analyzed and interpreted using log2 ratios
calculated by BlueFuse Multi software (BlueGnome, UK).
Embryos identified to be aneuploid (non-mosaic or mo-
saic) by CMA from TE specimens were reanalyzed, when
available, by FISH to confirm the array diagnosis. The
BlueFuse Multi software algorithm for making euploid
and aneuploid calls with 24sure arrays is based on the me-
dian log2 ratio of each chromosome. A chromosome gain
will be called when the median log2 ratio reaches +0.225
with 51% confidence in the call but will achieve 100% con-
fidence when the median ratio is ≥ +0.35. A chromosome
loss is called when the median log2 ratio is < -0.375 (51%
confidence) and at 100% confidence when the median
ratio is ≤ -0.6 (BlueGnome; personal communication).
In addition to software algorithms, there are inter-
experimental variables which also affect the ability to
define the limits of detection of mosaicism. These in-
clude variability in array lots, biopsy size, and integ-
rity of DNA in biopsied cells.
Embryo follow-up studies
Blastocysts used for quality assurance follow-up studies
were abnormal embryos donated for this purpose follow-
ing an informed consent process. Establishing a legal dis-
position for every embryo created by IVF is mandatory.
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is presented by a genetic counselor at the first PGD con-
sult and detailed in patient take-home PGD materials.
After getting this information, each patient must sign a
written consent for embryos disposition – embryos may
be frozen, discarded or donated to research. Patients are
aware these decisions are entirely voluntary and that they
will not directly benefit from them. The embryo donation
research consent includes permission to publish aggregate
data. The Genetics and IVF Institute (GIVF) Institutional
Review Board (IRB) is registered with the United States
Department of Health and Human Services (HHS) and
adheres to their guidelines for the protection of human
subjects. The research described in this publication con-
sisted of the analysis of existing data from donated spe-
cimens obtained by written informed consent for the
purpose of continuous PGD quality assurance (QA) moni-
toring. It was determined by the Chairperson of the GIVF
IRB that this study qualified as exempt research as pro-
mulgated by the U.S. Department of Health and Human
Services because the materials already existed for QA pur-
poses and the analysis of records presented no risk to
patients.
For FISH studies, blastocysts were dissociated by first
removing the zona pellucida with 1000 μs bursts from a
laser (Hamilton Thorne Biosciences, USA) or with treat-
ment with 0.1% pronase. Embryos were then placed in
50 μl of Ca/Mg-free medium with 5% HSA [QA Me-
dium with HEPES (Sage)/human serum albumin (100
mg/ml)] at room temperature for 15 minutes. Embryos
were transferred to a 2 μl droplet of hypotonic solution
(50% Dulbecco’s phosphate buffered saline) on a glass
slide for approximately 2 minutes. To the hypotonic so-
lution was added 15 μl of lysis solution (0.01 N HCl,
0.3% Tween 20). After approximately 10 minutes, most
cells will have separated from each other with the cell
membrane lysed. The slides were dried at room tem-
perature or on a 37°C slide warmer. Cells were fixed for
5 minutes in 50 ml of 2.5% buffered formalin phosphate
solution (Dulbecco’s phosphate buffered saline/10% buff-
ered formalin phosphate) before being rinsed in deion-
ized water and dehydrated for 5 minutes each in a 70%,
90%, and 100% ethanol series. Slides were dried at room
temperature. FISH probes (Abbott, USA) used in follow-
up studies targeted chromosomes identified to be abnor-
mal by CMA analysis. Because of reduced hybridization
efficiencies with multiple cycles of FISH on the same
cell, only 2-3 chromosomes were targeted in follow-up
in embryos containing multiple chromosome aneuploi-
dies identified by CMA. Probes and target DNA were
co-denatured at 75°C for 5 minutes using a HYBrite in-
strument (Abbott) and then transferred to a humidified
chamber at 37°C overnight. Following hybridization, slides
were first washed for 2 minutes in 0.4X SSC (sodiumchloride/sodium citrate) at 72-72°C and then in 2XSSC/
0.1% Igepal at room temperature for 1 minute. Slides were
then rinsed at room temperature in PN buffer (100 mM
Na2HPO4 / 50 mM NaH2 PO4 / 0.1% Igepal). Cells were
counterstained with DAPI (Abbott, USA) and approxi-
mately 25-35 nuclei with good signal intensity were scored
per embryo using a fluorescence microscope (Olympus)
and a 60X oil immersion objective. The interpretation of
interphase FISH data is subject to technical errors due
to overlapping, split, weak, or faded signals. From our
experience (unpublished data) and descriptions by others
[27], we estimate there is an approximate 10% total error
rate in FISH scoring when 2-3 probes are applied simul-
taneously. Therefore, we categorized embryos as non-
mosaic aneuploid when 90% or more cells were scored as
aneuploid and embryos as mosaic when < 90% of nuclei
but ≥ 10% of nuclei had an aneuploidy for any single
chromosome.
With an approximately 10% FISH error rate, it is pos-
sible that some abnormal embryos categorized by FISH
to be mosaic could, in fact, have been non-mosaic when
FISH results were near our upper threshold. In this in-
stance, however, FISH would still have confirmed an ab-
normality in the embryo. It is also possible that some
embryos with very low levels of mosaicism by FISH
could have been euploid. In our follow-up experiments,
however, very few embryos had FISH scores close to our
lower threshold and thus this would not have materially
affected the general conclusion of our study. Our CMA
studies were validated only for whole chromosome aneu-
ploidies and therefore, FISH follow-up data from em-
bryos suggestive of containing segmental aneuploidies
alone or in combination with other abnormalities were
excluded.Additional files
Additional file 1: Reconstitution Experiments – Chromosome Gains.
Individual log2 ratios and average log2 ratios were determined for
trisomy 13 and trisomy 21 samples at different levels of mosaicism.
Additional file 2: Reconstitution Experiments – Chromosome
Losses. Individual log2 ratios and average log2 ratios were determined
for monosomy 6 and monosomy 22 at different levels of mosaicism.
Additional file 3: Chromosomal microarray profiles of chromosomal
aneuploidy for a trisomy (+13). Images (A) - (F) showed different levels
of aneuploidy in the experimental samples: at 0, 25, 37.5, 50, 75 and
100%, respectively.
Additional file 4: Chromosomal microarray profiles of chromosomal
aneuploidy for a monosomy (-6). Images (A) - (F) showed different
levels of aneuploidy in the experimental samples: at 0, 25, 37.5, 50, 75
and 100%, respectively.
Additional file 5: Blind-test results of mosaic and non-mosaic
samples.
Additional file 6: Diagram of a reconstitution experiment. The visual
illustration of how reconstitution (mixing) experiments were performed in
this study.
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